Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
Introgen Therapeutics
ClinicalTrials.gov Identifier:
NCT00286247
First received: February 1, 2006
Last updated: March 28, 2008
Last verified: March 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given